Monday, July 22

Theralase Technologies shares update on Phase II Bladder Cancer study

–News Direct–

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive Bladder Cancer clinical study.

DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG).

Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. The interim clinical data for patients who received the optimized Study II Treatment is even more encouraging. At the 90 Day Assessment Visit, 62% of Evaluable Patients achieved a CR, and 68% achieved a Total Response (CR + IR). At 450 days, 39% achieved a CR, and 44% achieved a TR.

These positive results demonstrate the potential of Theralase Technologies' treatment approach in addressing Non-Muscle Invasive Bladder Cancer. The company continues to advance its research and clinical studies, bringing hope to patients and the medical community alike.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

View source version on

Theralase Technologies Inc

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No A News Week journalist was involved in the writing and production of this article.